Female fertility supplement protocol — what the trial evidence actually supports
Female fertility supplements range from items with strong neural-tube-defect-prevention evidence (folate, ideally as 5-MTHF) and oocyte-related trial signals (CoQ10 in older oocytes, myo-inositol in PCOS) to the much larger marketplace of "egg quality" stacks where the evidence is preliminary or absent. Reproductive medicine has converged on a small evidence-based supplement layer in trying-to-conceive populations; the broader supplement industry has not. This page focuses on what the trials actually show, with a deliberate emphasis on what to skip.
What actually has trial evidence
Folate as 5-MTHF (or folic acid), 400–800 mcg/day
400 mcg/day starting at least 1 month before conception; 800 mcg or higher in users with prior NTD pregnancy or specific risk factors
The single most evidence-anchored fertility-related supplement: periconceptional folate reduces neural tube defects by ~70%. Standard prenatal vitamins include this. 5-MTHF (methylfolate) is the active form and bypasses MTHFR enzyme variants; folic acid works for most users. Start at least 30 days before stopping contraception.
Vitamin D3 to a 25-OH-D target of 30–50 ng/mL
2,000 IU/day typically; test 25-OH-D and supplement to target
Vitamin D deficiency is associated with adverse pregnancy outcomes and possibly reduced fertility. Repleting deficiency before conception is reasonable. Above-target supplementation does not appear to add fertility benefit. Test and supplement to target rather than blind high-dose.
Myo-inositol (with D-chiro-inositol in 40:1 ratio)
2 g myo-inositol twice daily (4 g/day total); 3–6 months minimum
Multiple RCTs in PCOS show myo-inositol improves ovulatory function, insulin sensitivity, and may improve oocyte quality (Unfer 2017 meta-analysis). The 40:1 myo:D-chiro ratio approximates the natural balance. Cost-effective compared to metformin and often better tolerated.
CoQ10 (ubiquinol) 200–600 mg/day in older oocytes
200–600 mg/day ubiquinol form preferred, 3+ months prior to attempted conception or IVF cycle
Small trials in women undergoing IVF, particularly those 35+, suggest CoQ10 may improve oocyte quality markers and fertilisation rates (Bentov 2014; subsequent reviews). Effect size is small and trial quality is mixed. Reasonable for older oocytes; not high-yield for younger users without specific concern.
Omega-3 EPA/DHA, 1 g/day (≥200 mg DHA)
≥200 mg DHA/day preconception and during pregnancy
DHA is incorporated into fetal brain and retinal tissue; maternal DHA status during pregnancy influences cord-blood DHA. Some signals on preterm birth reduction at higher doses. Standard component of modern prenatal recommendations.
Iron (in iron-deficient women planning pregnancy)
Ferrous bisglycinate 30 mg elemental iron every other day, if ferritin < 30–50 ng/mL
Iron deficiency is common in menstruating women and is associated with worse pregnancy outcomes if uncorrected. Test ferritin before supplementing routinely; over-supplementation in iron-replete women is not benign.
What dominates over supplements
- Cycle tracking and timed intercourse — ovulation prediction kits or fertility-awareness methods produce conception rate increases that supplement stacks don't approach.
- BMI normalisation — both overweight and underweight depress fertility; small body composition changes improve ovulatory function meaningfully.
- Smoking cessation — both partners; smoking is a major modifiable cause of subfertility and miscarriage.
- Moderate alcohol reduction — heavy alcohol intake depresses fertility; the safest preconception threshold is none, particularly close to ovulation.
- Sleep quality — shift work and chronic short sleep are independently associated with reduced fertility.
- Stress and mental health — fertility journeys are stressful; CBT, mindfulness, and structured psychological support improve outcomes and quality of life.
- Specialty evaluation — semen analysis (the cheapest, fastest fertility diagnostic; under-utilised), tubal patency studies, ovulation assessment, ovarian reserve testing.
What to skip
- "Fertility blends" with rooibos, vitex/chasteberry, maca, dong quai, and various honourable mentions — most ingredients lack RCT evidence in fertility; some have hormonal effects with insufficient safety data periconceptionally. Vitex in particular can be counterproductive depending on cycle phase.
- Megadose vitamin A retinol — chronic vitamin A > 10,000 IU/day is teratogenic; avoid high-dose vitamin A periconceptionally. Beta-carotene is safe; preformed retinol at high doses is not.
- DHEA in women without diminished ovarian reserve diagnosis — used in some fertility clinics for diminished ovarian reserve under specialist supervision, with mixed evidence; routine supplementation in non-DOR women is not indicated and has androgenic side effects.
- "Detox" cleanses, parasite cleanses, and elimination protocols — no fertility evidence; some are nutritionally compromised.
- High-dose antioxidant cocktails — the Cochrane review on antioxidants for female subfertility (2020) found low-quality evidence of any effect on live birth rate.
- CBD products marketed for fertility — no evidence; theoretical concerns periconceptionally.
- Black cohosh near conception — used for menopausal symptoms; not appropriate periconceptionally.
What to track
Conception is the primary endpoint; ovulation tracking (basal body temperature, LH kits) and cycle regularity are good interim metrics. For users with PCOS: cycle regularity and ovulation are direct markers of myo-inositol response. For users with vitamin D deficiency: serum 25-OH-D rise to target. Reassess at 3 months of supplement protocol if conception has not occurred and you've passed the "seek evaluation" threshold (12 months trying, or 6 months if 35+).